A prospective clinical trial of the second-look procedure for transoral surgery in patients with T1 and T2 laryngeal, oropharyngeal, and hypopharyngeal cancer.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
12 2019
Historique:
received: 31 07 2019
revised: 10 09 2019
accepted: 15 09 2019
pubmed: 9 10 2019
medline: 25 9 2020
entrez: 10 10 2019
Statut: ppublish

Résumé

Transoral surgery (TOS) has been widely applied for early T-stage head and neck cancer (HNC). The resection is performed with a minimum safety margin for function preservation under a limited surgical field; therefore, it is difficult to have a strong conviction about the complete resection. This study aims to evaluate the completeness of the initial TOS procedure; possibility of primary control by TOS alone; and predictive factors in patients with early T-stage laryngeal, oropharyngeal, and hypopharyngeal cancer. Patients were treated by TOS at the primary site with or without neck dissection. The patients were divided into two groups based on the pathological evaluation of their surgical specimens: the control (observation) group, in that the resection was considered complete and the intervention (second-look procedure) group, in that incomplete tumor resection was suspected. The predictive factors for the possibility and/or limitations of complete resection by TOS were then analyzed. The study enrolled 26 and 25 patients in the control and intervention group, respectively. The success rate for single resection was 66% and the predictive factor was tumor depth obtained by enhanced computed tomography (CT) examination (odds ratio, 7.870, P = .0243). The success rate for definitive therapy by TOS alone was 83% and the predictive factor was poor differentiation observed on pathological examination (odds ratio, 6.800, P = .0248). TOS has the potential for both definitive resection and function preservation with minimal invasiveness. Identification of the risk factors for TOS is advantageous for accurate treatment selection in patients with early T-stage HNC.

Sections du résumé

BACKGROUND
Transoral surgery (TOS) has been widely applied for early T-stage head and neck cancer (HNC). The resection is performed with a minimum safety margin for function preservation under a limited surgical field; therefore, it is difficult to have a strong conviction about the complete resection. This study aims to evaluate the completeness of the initial TOS procedure; possibility of primary control by TOS alone; and predictive factors in patients with early T-stage laryngeal, oropharyngeal, and hypopharyngeal cancer.
METHODS
Patients were treated by TOS at the primary site with or without neck dissection. The patients were divided into two groups based on the pathological evaluation of their surgical specimens: the control (observation) group, in that the resection was considered complete and the intervention (second-look procedure) group, in that incomplete tumor resection was suspected. The predictive factors for the possibility and/or limitations of complete resection by TOS were then analyzed.
RESULTS
The study enrolled 26 and 25 patients in the control and intervention group, respectively. The success rate for single resection was 66% and the predictive factor was tumor depth obtained by enhanced computed tomography (CT) examination (odds ratio, 7.870, P = .0243). The success rate for definitive therapy by TOS alone was 83% and the predictive factor was poor differentiation observed on pathological examination (odds ratio, 6.800, P = .0248).
CONCLUSIONS
TOS has the potential for both definitive resection and function preservation with minimal invasiveness. Identification of the risk factors for TOS is advantageous for accurate treatment selection in patients with early T-stage HNC.

Identifiants

pubmed: 31595716
doi: 10.1002/cam4.2588
pmc: PMC6885886
doi:

Types de publication

Clinical Trial Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

7197-7206

Informations de copyright

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Ann Otol Rhinol Laryngol. 2010 Apr;119(4):225-32
pubmed: 20433020
Cancer Med. 2019 Dec;8(17):7197-7206
pubmed: 31595716
Endoscopy. 2008 Sep;40 Suppl 2:E189-90
pubmed: 18709610
Eur Arch Otorhinolaryngol. 2015 Aug;272(8):2001-6
pubmed: 24939176
J Clin Oncol. 2006 Jun 10;24(17):2636-43
pubmed: 16763277
Endoscopy. 2012 Jun;44(6):556-64
pubmed: 22638778
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5
pubmed: 18635320
Arch Otolaryngol. 1984 Sep;110(9):564-5
pubmed: 6477272
Head Neck. 2017 Jan;39(1):71-81
pubmed: 27453475
Head Neck. 2016 Oct;38(10):1467-71
pubmed: 27080244
AJR Am J Roentgenol. 2005 Apr;184(4):1326-31
pubmed: 15788619
Anticancer Res. 2009 Feb;29(2):661-6
pubmed: 19331217
Head Neck. 2017 Aug;39(8):1631-1638
pubmed: 28474378
Surg Today. 2014 Sep;44(9):1603-10
pubmed: 23989943
Int J Clin Oncol. 2016 Oct;21(5):869-874
pubmed: 26908193
Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):743-51
pubmed: 15183477
Ann Otol Rhinol Laryngol. 2007 Jan;116(1):19-23
pubmed: 17305273
Otolaryngol Head Neck Surg. 2008 Apr;138(4):446-51
pubmed: 18359352
Eur Arch Otorhinolaryngol. 2017 Apr;274(4):1997-2004
pubmed: 28028607
Head Neck. 2013 Aug;35(8):1162-7
pubmed: 22972757
JMIR Res Protoc. 2017 Dec 05;6(12):e235
pubmed: 29208591
Head Neck. 2017 Jun;39(6):1166-1176
pubmed: 28252821
Head Neck. 2011 Sep;33(9):1315-21
pubmed: 21837702

Auteurs

Goshi Nishimura (G)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Daisuke Sano (D)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Yasuhiro Arai (Y)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Takashi Hatano (T)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Hideaki Takahashi (H)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Teruhiko Tanabe (T)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Takashi Wada (T)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Daiki Morishita (D)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Nobuhiko Oridate (N)

Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH